Androgen receptor as prognostic marker in triple-negative breast cancer patients
Loading...
Official URL
Full text at PDC
Publication date
2018
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Longdom Group
Citations
Exportar
Citation
MA Cabezas-Quintario, V Zenzola, M Arguelles, E Perez-Fernandez. Androgen Receptor as Prognostic Marker in Triple-Negative Breast Cancer Patients. Journal of Medical & Surgical Pathology [Internet]. 2018;03(04). Available from: http://dx.doi.org/10.4172/2472-4971.1000170
Abstract
Purpose: The purpose of this study was to assess the prognostic impact of androgen receptor (AR) expression in
patients with triple-negative breast cancer (TNBC).
Methods/patients: 101 patients treated for primary TNBC without distant metastasis from 1999 to 2015 were
identified from breast surgery database. Kaplan-Meier and Cox regression models evaluated disease-free survival
(DFS) and overall survival (OS).
Results: AR expression was positive (IHC>1%) in 40% of patients. OS at 36 and 60 months was 86% and 80%
in AR-negative patients, and 100% and 96% in AR-positive patients (log rank test 0.036). DFS at 36 and 60 months
was 78% and 68% in AR-negative and 92% and 89% in AR-positive (log rank test 0.075).
Conclusions: Patients without AR expression have a significant correlation with poor outcome